|
1）厚生労働省医薬食品局審査管理課. コンパニオン診断薬等及び関連する医薬品の承認申請に係る留意事項について．2013. http://www.pmda.go.jp/files/000157904.pdf
|
|
|
|
|
2）独立行政法人医薬品医療機器総合機構. コンパニオン診断薬及び関連する医薬品の開発に関する技術的ガイダンス．2013.http://www.pmda.go.jp/files/000157570.pdf
|
|
|
|
|
|
3）Seto T, Kiura K, Nishio M, et al. CH5424802 （RO5424802） for patients with ALK-rearranged advanced non-small-cell lung cancer （AF-001JP study）: a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013; 14: 590-8
|
|
|
|
|
4）日本肺癌学会. ALK融合遺伝子のコンパニオン診断薬についての声明．2014. https://www.haigan.gr.jp/modules/bulletin/
|
|
|
|
|
|
5）Pignatti F. How to regulate emerging technologies: EMA view. Brussels; 2013. [updated Dec 12-13]. http://www.bdaoncology.org/docs/2013companionfp.pdf
|
|
|
|
|
|
6）He M, Capelletti M, Nafa K, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012; 18: 1790-7
|
|
|
|
|
|
7）Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2011; 2045: 1-9
|
|
|
|
|
|
8）Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012; 23: 2914-9
|
|
|
|
|
|
9）日本肺癌学会. ALK融合遺伝子陽性非小細胞肺癌診断のためのVentana社高感度免疫染色法の早期承認に関する要望書．2015. https://www.haigan.gr.jp/modules/bulletin/index.php?page=article&storyid=93
|
|
|
|
|
|
10）Hammerling JA. A review of medical errors in laboratory diagnostics and where we are today. Lab Med. 2012; 43: 41-4
|
|
|
|
|